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Research
Nanotechnology holds great promise in
numerous fields, including medicine.
However, concerns have been expressed about
possible adverse effects of nanomaterials (Hoet
et al. 2004; Oberdörster et al. 2005b; Xia
et al. 2006). Although such concerns may
have been exaggerated, they are not entirely
without foundation (Maynard 2006), and it is
fair to state that research and development of
novel technologies, such as nanotechnology,
often take place without much regard for
potential harmful effects on the environment
and/or human health (Maynard 2006). The
medical applications of quantum dots (QDs)
represent a case in point.
Nanosized QDs have speciﬁc properties—
tunable emission wavelength, broadband
absorption spectrum, and photostability—that
make them ideal diagnostic probes for long-
term in vivo and in vitro (multicolor) imaging
(Ballou et al. 2004; Jaiswal et al. 2003; Larson
et al. 2003; Medintz et al. 2005; Michalet
et al. 2005; So et al. 2006) and site-speciﬁc tar-
geting of drugs (Akerman et al. 2002; Gao
et al. 2004; Stroh et al. 2005; Tada et al. 2007;
Yu et al. 2007). The existing knowledge of the
hazard of QDs is very incomplete, certainly
compared with drugs or other chemical agents
(Hardman 2006). Although the in vitro cyto-
toxicity of QDs has been studied (Derfus et al.
2004; Kirchner et al. 2005; Lovric et al.
2005a, 2005b; Shiohara et al. 2004), little or
no attention has been paid to their potential
in vivo toxicity (Ballou et al. 2004; Kim et al.
2004; Larson et al. 2003). Recently, some
studies (Fischer et al. 2006; Gopee et al. 2007;
Soo Choi et al. 2007; Yang et al. 2007) have
investigated the biodistribution of QDs.
However, most information on their in vivo
toxicity—or the alleged lack of it—has been
derived from studies that were not speciﬁcally
designed to evaluate toxicity.
In the present study, we investigated the
acute in vivo toxicity, including systemic and
pulmonary inﬂammation, tissue distribution,
and prothrombotic effects, of commercially
available cadmium selenide/zinc sulfide
(CdSe/ZnS) QDs. To assess the importance of
surface charge, we studied QDs with different
surface modifications [with carboxyl surface
coating (carboxyl-QDs) or with amine surface
coating (amine-QDs)]. We performed a
detailed particle characterization, as has been
recommended when studying the hazards of
nanomaterials (Oberdörster et al. 2005a).
Various doses—within the range of those used
for in vivo applications (Ballou et al. 2004; Gao
et al. 2004; Kim et al. 2004; So et al. 2006)—
were intravenously (iv) administered to mice.
In the ﬁrst set of experiments, we administered
relatively high doses (3,600, 720, or
144 pmol/mouse) and performed analyses after
1 hr. In the second set of experiments, lower
doses (144, 14.4, or 1.44 pmol/mouse) were
injected, and toxic effects were assessed over
time (1, 4, or 24 hr). Because initial observa-
tions showed that injected QDs affected hemo-
stasis, with vascular thrombi being produced in
the lung circulation, we investigated the effect
of an anticoagulant (heparin) on thrombosis
in vivo and the effect of QDs on murine and
human platelet aggregation in vitro. To our
knowledge, this is the ﬁrst comprehensive eval-
uation of the in vivo toxicity, prothrombotic
effects, and biodistribution of injected QDs.
Materials and Methods
Particle characterization. Type I EviTags
(Evident Technologies, New York, New York,
USA) are core/shell QDs consisting of
CdSe/ZnS. We used Catskill green, carboxyl
or amine modified QDs (carboxyl-QDs and
amine-QDs, respectively), purchased in a solu-
tion of approximately 9 nmol/mL QDs (or
0.25 mg/mL QDs). To ensure the quality of
the QDs, we ran all experiments within
3 months after purchase and kept QDs in dark
and refrigerated conditions. For the ﬁrst set of
experiments (144–3,600 pmol/mouse), this
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BACKGROUND: Quantum dots (QDs) have numerous possible applications for in vivo imaging.
However, toxicity data are scarce.
OBJECTIVES: To determine the acute in vivo toxicity of QDs with carboxyl surface coating (carboxyl-
QDs) and QDs with amine surface coating (amine-QDs), we investigated the inﬂammatory proper-
ties, tissue distribution, and prothrombotic effects after intravenous injection.
METHODS: We performed particle characterization by transmission electron microscopy and dynamic
light scattering. Carboxyl-QDs and amine-QDs were intravenously injected in mice
(1.44–3,600 pmol/mouse). At different time intervals, analyses included ﬂuorescence microscopy,
blood cell analysis, bronchoalveolar lavage, wet and dry organ weights, and cadmium concentration in
various organs. We examined the prothrombotic effects in vivo by assessing the effect of pretreatment
with the anticoagulant heparin and by measuring platelet activation (P-selectin), and in vitro by platelet
aggregation in murine and human platelet-rich plasma exposed to QDs (1.44–1,620 pmol/mL).
RESULTS: At doses of 3,600 and 720 pmol/mouse, QDs caused marked vascular thrombosis in the
pulmonary circulation, especially with carboxyl-QDs. We saw an effect of surface charge for all the
parameters tested. QDs were mainly found in lung, liver, and blood. Thrombotic complications were
abolished, and P-selectin was not affected by pretreatment of the animals with heparin. In vitro,
carboxyl-QDs and amine-QDs enhanced adenosine-5´-diphosphate–induced platelet aggregation.
CONCLUSION: At high doses, QDs caused pulmonary vascular thrombosis, most likely by activating
the coagulation cascade via contact activation. Our study highlights the need for careful safety
evaluation of QDs before their use in human applications. Furthermore, it is clear that surface
charge is an important parameter in nanotoxicity.
KEY WORDS: blood cell analysis, coagulation, intravenous, in vivo, nanoparticles, platelet aggrega-
tion, quantum dots, surface charge, thrombosis, toxicity. Environ Health Perspect 116:1607–1613
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evaporation of the solvent; for the second set of
experiments (1.44–144 pmol/mouse), we used
the original solution.
Particle size and distribution of the original
solution and the concentrated solution were
measured by dynamic light scattering (DLS),
using a Malvern Zetasizer Nano-ZS (Malvern
Instruments Ltd., Worcestershire, UK). To
this end, 2 µL particles was dispersed in
800 µL water, Hanks’ Balanced Salt Solution
(HBSS; Gibco, Merelbeke, Belgium), saline
(0.9% NaCl), or medium Dulbecco’s
Modified Eagle Medium (DMEM; Gibco).
We performed three series of 15 measurements
and calculated the average particle size. The
zeta potential was calculated from electro-
phoretic mobility measurements in ﬁve series
of 30 measurements (Malvern Zetasizer Nano-
ZS; Malvern Instruments Ltd.). The isoelectric
point (IEP) was determined in water by meas-
uring the change in electrophoretic mobility as
a function of pH: the solution to a pH of
approximately 10 and acid was introduced—
step by step—automatically by the Malvern
Zetasizer. At each point, the zeta potential and
size were measured. The IEP was calculated as
the pH value when the charge around the par-
ticle becomes zero, that is, a net neutral surface
charge. Sample preparation for transmission
electron microscopy (TEM) consisted of plac-
ing a volume of 0.5 µL QDs on TEM copper
grids (400 mesh) with a holey carbon ﬁlm. The
grids were then dried for 2–3 hr in a desiccator
under vacuum. TEM pictures were taken using
a JEOL 2010 microscope (JEOL Ltd.,
Hertfordshire, UK).
Animals. Male Balb/c mice (20–23 g;
Janvier Co., Uden, The Netherlands) received
an iv injection in the tail vein (5 cm from dis-
tal end), while being held in a restraining
device. A bolus injection of 40 µL sterile
saline (0.9% NaCl) containing QDs or 40 µL
saline (controls) was given using a plastic
0.3-mL syringe of U-100 insulin (BD Micro-
fine; BD, Erembodegem, Belgium). We ran
experiments on different days with the doses
randomly organized, although we included at
least one control each day. All experimental
procedures were approved by the local ethical
committee for animal experiments. Animals
were treated humanely and with regard for
alleviation of suffering.
Experimental design. In the first set of
experiments, 1 hr after injecting QDs
(144–3,600 pmol/mouse), we removed the
lung, heart, liver, kidneys, spleen, and brain
for analysis by fluorescence microscopy. At
the same time point, for QDs doses of
144–720 pmol/mouse, blood was collected, a
bronchoalveolar lavage (BAL) was performed
(right lung), and the weight (wet and after dry-
ing) of left lung, heart, liver, kidneys, spleen,
and brain were recorded. Furthermore, in these
organs and in the blood, we measured the Cd
concentration to assess the tissue distribution.
In a separate experiment, mice were pre-
treated with the anticoagulant heparin and a
dose of QDs of 720 pmol/mouse was adminis-
tered. One hour after injection, the blood was
analyzed and the lung and liver were removed
for evaluation by ﬂuorescence microscopy. We
performed ﬂow cytometry to assess the expres-
sion of P-selectin on activated platelets.
In the second set of experiments, lower
doses of QDs (1.44–144 pmol/mouse) were
injected, and analyses were performed after 1,
4, and 24 hr: blood analysis, BAL, and wet
and dry weight of left lung, liver, kidneys, and
spleen. The Cd concentration was measured
in lung, liver, and blood. We also performed
in vitro platelet aggregation studies with
human and murine platelet-rich plasma
(PRP), as described below.
Blood analysis. At 1, 4, or 24 hr after
administration of QDs, the animals were
anesthetized with 1.2 mg/kg pentobarbital
(Nembutal; Ceva Sante Animale, Brussels,
Belgium), and a blood sample was taken from
the retroorbital plexus, using a heparinized
capillary tube (Na-heparin minicaps;
Hirschmann Laborgeräte, VWR, Haasrode,
Belgium) filled with 4% sodium citrate
(Sigma, Bornem, Belgium). The blood was
collected in a tube containing heparin (BD
microtainer with heparin) and analyzed for
the number of erythrocytes, platelets, and
total leukocytes, as well as neutrophils,
lymphocytes, monocytes, eosinophils, and
basophils (Cell-Dyn system 3500; Abbott
Laboratories, Louvain-la-Neuve, Belgium).
Fluorescence microscopy. Animals were sac-
rificed 1 hr after injection of the QDs, by
intraperitoneal injection of 90 mg/kg pentobar-
bital (Nembutal). A full-body perfusion via the
left ventricle (with open vena cava) using a pres-
sure of 1 m H2O was performed with 0.9%
NaCl, followed by ﬁxation with 4% formalde-
hyde (VWR, Haasrode, Belgium). We collected
the organs and stored them separately in 4%
formaldehyde for 24 hr and then in Sörensen
buffer (Sigma). Pieces of each organ were
embedded in parafﬁn wax and two sequential
slices were prepared: one was stained with
hematoxylin and eosin (H&E), and the other
was not stained. Digital images were taken with
an AxioCam HRc camera and AxioPlan micro-
scope, both from Zeiss (Zaventem, Belgium).
BAL and wet and dry organ weight. After
sacriﬁcing the animals, the chest was opened
and the left lung was clamped, removed, and
weighed (wet weight). After drying the lung
at 70°C, we determined the dry weight. We
also determined the wet and dry weights of
other organs.
The right lung was lavaged three times with
0.4 mL sterile saline (0.9% NaCl). The recov-
ered BAL fluid was pooled and centrifuged
(2,000 × g for 10 min, 4°C). For differential
cell counts, 250 µL of the resuspended cells
(200,000 cells/mL) was spun (1,400 × g for
6 min; Shandon Cytospin 3; TechGen, Zellik,
Belgium) onto microscope slides, air dried, and
stained (Diff-Quik method). We then analyzed
3 × 100 cells for the presence of macrophages,
eosinophils, neutrophils, or lymphocytes. We
did not perform full-body perfusion in this part
of the experiment.
Assessing tissue distribution by measuring
Cd concentration. After a full-body perfusion
with sterile 0.9% NaCl, organs were collected.
After drying, the organs were dissolved in 3 mL
ultrapure nitric acid 60% (Sigma) in a water
bath at 80°C, the Cd concentration was meas-
ured by inductively coupled plasma–optical
emission spectrometry (ICP-OES; Optima
3300DV; Perkin Elmer, Zaventem, Belgium).
The detection limit was 0.002 mg Cd/L, but
only measurements > 0.006 mg Cd/L were con-
sidered positive. We calibrated the instrument
with ICP Multi Element Standard Solution IV
CertiPur (Sigma) containing 0.5 mg/L or
5 mg/L Cd. Blanks containing only nitric acid
were measured as a negative control. The Cd
concentration in the tissues is expressed on a wet
weight basis, with mean ± SD weights of 1.275
± 0.170 g for liver and 0.128 ± 0.032 g for lung,
thus resulting in a detection limit of 0.014 µg
Cd/g wet weight in liver and of 0.140 µg Cd/g
wet weight in lung. In the high-dose experi-
ments, 240 ± 48 µL blood was collected with a
detection limit of 0.075 µg Cd/mL blood; in
the low-dose experiments, 676 ± 98 µL blood
was collected, resulting in 0.027 µg Cd/mL
blood as the detection limit. The correlation
between the amount of QDs and the concentra-
tion of Cd was obtained through a standard
curve (1.08–90 pmol QDs).
Investigation of prothrombotic effects
in vivo. Hemostasis is subdivided into a pri-
mary and secondary cascade. The ﬁrst refers to
processes relating to platelet activation; the sec-
ond, to processes of coagulation. Both processes
are intertwined and occur to varying degrees in
the arterial and venous circulation. We investi-
gated whether the thrombosis was a result of
activation of the coagulation cascade by admin-
istering QDs in mice pretreated with the anti-
coagulant heparin. Two minutes before iv
injection of QDs (720 pmol/mouse; n = 3) or
saline (n = 3), mice received an intraperitoneal
injection of heparin (10 U, in 200 µL saline).
One hour later, blood was sampled from the
retroorbital plexus and cells were counted, as
described above. After a full-body perfusion, we
prepared the lung and liver of the mice for ﬂuo-
rescence microscopy, as described above. In
addition, in the same animals, blood was
collected to assess P-selectin as a measure of
platelet activation. For this purpose, blood was
collected from the retroorbital plexus, using a
heparinized capillary tube filled with 4%
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taining 20 µg/mL hirudin. This blood sample
(100 µL) was ﬁxed for 1 hr at 4°C in 900 µL
diluted CellFix solution (BD). The ﬁxed blood
was centrifuged for 5 min at 2,000 rpm, the
pellet was resuspended in 1 mL phosphate-
buffered saline (PBS), and centrifuged for
5 min at 1,200 rpm. The pellet was kept at 4°C
until analysis, within 5 hr. 
For the analysis, the pellet was resuspended
in 70 µL PBS with 20 µL blocking rat serum
and 10 µL of an anti-CD62P antibody (phyco-
erythrin-labeled rat anti-mouse P-selectin;
Emfret Analytics, Würzburg, Germany), and
incubated for 20 min in the dark. Immediately
after dilution to 1 mL with PBS, the samples
were acquired on a FACSCaliber ﬂow cytome-
ter (BD) and the presence of P-selectin was
investigated in the window of the platelets.
In vitro platelet aggregation tests. We
investigated whether the thrombosis resulted
from activation of platelets by performing
platelet aggregation tests. We prepared PRP
by centrifuging citrated blood from untreated
Balb/c mice and from six human healthy vol-
unteers (men) who had not taken drugs, as
previously described (Freson et al. 2001; Oury
et al. 2003). The platelet count was adjusted
to 0.25 × 106 platelets/µL, via dilution in
autologous plasma. We induced platelet aggre-
gation, followed on a Chrono-log aggregome-
ter (Kordia, Leiden, The Netherlands), with
the agonist ADP (adenosine-5´-diphosphate),
at 5 µM for murine platelet aggregation and
0.625, 1, or 1.5 µM for human platelet aggre-
gation, depending on the response of the
donor platelets to ADP. We added ADP
1 min after preincubation of the PRP with
QDs and induction of stirring. We then
added either carboxyl-QDs or amine-QDs to
the plasma (1.44–1,620 pmol/mL). Tests were
also performed without ADP.
Statistical analysis. We analyzed differ-
ences between groups by one-way analysis of
variance followed by Newman-Keuls test; the
BAL samples were compared with a Student’s
t-test (GraphPad Prism Package; GraphPad
Software, San Diego, CA, USA). We consid-
ered p-values < 0.05 to be signiﬁcant.
Results
Particle characterization. We examined the
QDs by TEM (Figure 1). The structured
cores/shells of different QDs are apparent; the
coating appears as an irregular mass in the
background. With DLS and electrophoretic
mobility, we measured the size and zeta poten-
tial in different vehicles, as listed in Table 1.
According to the technical information and
the material safety data sheets provided by
the manufacturer, the QDs we used have a
Acute toxicity of quantum dots in mice
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Table 1. Physical characterization of the QDs.
Vehicle Diameter (nm)a Polydispersity index Zeta potential (mV) IEP
Amine-QDs
DI Water 77.3 0.285 –32.2 pH 3.19
DI Water × 10b 137 0.331
HBSS 80.5 0.249 –17.3
Saline 93.3 0.328 –14.2
DMEM 79.8 0.234 –12.0
Carboxyl-QDs
DI water 35.9, 186c 0.495 –57.7 pH 1.71
DI water ×10b 46.5, 188, 1,280c 0.946
HBSS 84.5 0.291 –24.5
Saline 104 0.352 –35.2
DMEM 107 0.439 –24.3
DI, deionized.
aAverage diameter from intensity distribution, measured by DLS. bThe QDs were concentrated 10-fold through evapora-
tion of the solvent. cSamples were polydispersed, with the coexistence of two/three particle sizes.
Figure 1. TEM of amine-QDs. The core/shell of the
QDs can be seen as structured elements (arrow-
heads); the coating is spread as a layer over the
whole grid. Bar = 5 nm.
Figure 2. Size distribution by intensity, measured with DLS, of amine-QDs (A) and carboxyl-QDs (B) in water
(1), HBSS (2), saline (3), DMEM (4), or water after 10-fold concentration through evaporation of the solvent (5).
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Figure 3. Fluorescence microscopy 1 hr after iv administration of QDs in mice. (A and B) Lung of mouse
dosed with 3,600 pmol amine-QDs (A) or carboxyl-QDs (B). Arrows indicate fluorescent QDs in thrombi;
note the difference in number of thrombi in (A) and (B). (C and D) Enlargement of thrombi (arrows) shown
in (B). No platelets can be seen inside the thrombi in either nonstained sections (C) or H&E-stained sec-
tions (D); instead, ﬁbrin ﬁbers are present. (E) Liver of a mouse injected with 3,600 pmol amine-QDs; the
arrows indicate QDs. (F) H&E staining of lung from a mouse pretreated with heparin and dosed with
720 pmol carboxyl-QDs shows complete absence of thrombi. Bars = 50 μm.
A
B
C
D
E
Fhydrodynamic diameter of approximately
40 nm. We found that the amine-QDs and
carboxyl-QDs differed in diameter and poly-
dispersity index, depending on the vehicle.
Moreover, when we concentrated the QDs
10-fold, the particles tended to aggregate, and
this was more pronounced with carboxyl-QDs
than with amine-QDs, as illustrated in
Figure 2. Both QDs have a negative zeta
potential in all tested vehicles, but the car-
boxyl-QDs are 2-fold more negative than the
amine-QDs (Table 1).
The core of the QDs consists of CdSe.
Measurements in two different batches of par-
ticles revealed that approximately 27% of the
QD mass consists of Cd (0.833 µg/mL QDs
contains 0.23 mg/L Cd). The linear cor-
relation (R2 = 0.9997) between Cd and QD
concentration enables a quantiﬁcation of the
QDs in blood or tissues, down to 2.52 pmol.
High doses of QDs: analysis 1 hr after
injection. After iv injection of 3,600 pmol/
mouse of carboxyl-QDs, three out of four mice
died immediately; no deaths were recorded
after injection of amine-QDs. After iv injection
of 720 or 144 pmol/mouse, all mice showed
signs of discomfort, such as labored breathing
and piloerection, but no deaths occurred.
Fluorescence microscopy revealed that par-
ticles were present in the lung and liver.
Moreover, thrombi containing ﬂuorescent QDs
were apparent in the lung (Figure 3A,B). The
number of thrombi was manifestly higher in
animals injected with carboxyl-QDs than in
those injected with amine-QDs. We found
fewer thrombi at lower doses. H&E staining
showed the presence of ﬁbrin-rich thrombi in
the lung circulation (Figure 3C,D). Fluorescent
spots could also be found in the liver of mice
treated with 3,600 pmol amine-QDs, but not
at lower doses, and not with carboxyl-QDs
(Figure 3E). We found no evidence of thrombi
when the mice had been treated with heparin
before injection of QDs (720 pmol; Figure 3F).
One hour after dosing with 720 pmol/
mouse of carboxyl-QDs, the platelet count was
signiﬁcantly reduced (Figure 4A). With amine-
QDs, we saw only a slight decrease, reaching
signiﬁcance for 144 pmol/mouse. No changes
occurred in total blood leukocyte numbers or
in the percentages of neutrophils, lymphocytes,
or monocytes (data not shown). In the BAL
fluid, we found no influx of neutrophils or
lymphocytes (data not shown). The wet and
dry weights of the organs of mice injected with
QDs were not different from those of controls
(data not shown).
Pretreatment with heparin before injection
of 720 pmol QDs abolished the drop in
platelet count (Figure 4A). Flow cytometry
showed that the platelet P-selectin levels in
mice injected with QDs did not differ from
those in control mice (data not shown); that is,
we saw no evidence of in vivo platelet activa-
tion in the presence of heparin.
The Cd concentration was below the detec-
tion limit in all the collected organs of control
animals. In animals treated with QDs, the Cd
concentration in lung and liver was dose-depen-
dently increased (Figure 4B,C). We found up
to 15 µg Cd/g lung in animals that received
720 pmol of carboxyl-QDs, corresponding to
39% of the initial injected dose (Table 2).
Animals dosed with 144 pmol carboxyl-QDs
had a mean Cd content of 0.37 µg/g lung (a
total of 0.048 µg Cd in lung), corresponding to
4% of the initial injected dose. The amount of
Cd in the lungs of animals receiving amine-
QDs was lower. In the liver, we found higher
amounts of amine-QDs compared with car-
boxyl-QDs: 0.90 µg Cd/g liver and 0.33 µg
Cd/g liver for 720 and 144 pmol amine-QDs,
respectively, corresponding to 24% and 34% of
the administered dose. In the blood, we found
Cd only in mice that received amine-QDs
(Figure 4D, Table 2). In the other organs
tested, Cd concentrations were below the detec-
tion limit (data not shown).
Low doses of QDs: analysis at different
time points. To further assess toxicity over
time (1, 4, and 24 hr), we selected doses that
did not elicit noticeable acute symptoms in
the mice (1.44–144 pmol/mouse). These
doses are in the range of those used for in vivo
applications (Kim et al. 2004; So et al. 2006).
These doses did not decrease the number
of platelets (data not shown). However, the
percentage of neutrophils in blood signiﬁcantly
increased from 20% to 47% 4 hr after inject-
ing 144 pmol of carboxyl-QDs; in parallel, the
percentage of lymphocytes decreased from
75% to 48% (Figure 5). Absolute numbers of
neutrophils significantly increased 1 hr after
administering 144 pmol amine-QDs (2.77 ±
0.70 × 103/µL vs. 1.54 ± 0.43 × 103/µL
neutrophils in controls, p < 0.05) and 4 hr after
144 pmol carboxyl-QDs (2.40 ± 0.98
× 103/µL vs. 1.42 ± 0.28 × 103/µL neutrophils
in controls; p < 0.05). The number of mono-
cytes was increased 4 hr after injecting
144 pmol carboxyl-QDs (0.46 ± 0.33
× 103/µL vs. 0.17 ± 0.13 × 103/µL monocytes
Geys et al.
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Table 2. Cd measurement 1 hr after iv administration of carboxyl-QDs or amine-QDs (144 or 720 pmol/mouse).
Dose Lung Liver
(pmol/mouse) Total Cd (μg)a Percentb Total Cd (μg)a Percentb Blood (%)b
Carboxyl-QDs
144 0.048 ± 0.042 4.4 ± 3.8 0.054 ± 0.028 4.9 ± 2.6 NDc
720 2.152 ± 0.386 39.1 ± 7.1 0.214 ± 0.017 3.9 ± 0.3 NDc
Amine-QDs
144 0.043 ± 0.018 3.9 ± 1.7 0.377 ± 0.058 34.3 ± 5.2 2.3 ± 0.6
720 0.608 ± 0.500 11.0 ± 9.1 1.315 ± 1.227 23.9 ± 22.3 1.3 ± 0.3
ND, not detectable. Values are mean ± SD from two to three animals.
aTotal Cd in organ. bPercentage of the injected Cd dose. c< 0.006 mg/L Cd. 
Figure 4. Effects and tissue distribution 1 hr after iv administration of carboxyl-QDs or amine-QDs (144 or
720 pmol/mouse). ND, below detection limit of 0.006 mg/L Cd. (A) Number of platelets in blood. Open
squares and circles represent mice pretreated with heparin. (B–D) Tissue distribution based on the con-
centration of Cd in lung (B), liver (C), and blood (D). Horizontal bars represent the means. Blood analysis:
control, n = 9; treatment, n = 4–5. Lung and liver analysis: control, n = 4; treatment, n = 2–3.
*p < 0.05. #p < 0.001.
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C Din controls, p < 0.05) and 144 pmol amine-
QDs (0.48 ± 0.18 × 103/µL vs. 0.17 ± 0.13
× 103/µL monocytes in controls; p < 0.05).
We found a signiﬁcant increase in the num-
ber of macrophages in BAL ﬂuid (28 ± 18 ×
103 macrophages in control) 4 hr after adminis-
tering 1.44 pmol carboxyl-QDs (88 ± 46 × 103
macrophages; p < 0.01) and 14.4 pmol amine-
QDs (56 ± 22 × 103 macrophages; p < 0.05).
The wet and dry weights of the lung, liver, kid-
ney, and spleen of mice injected with QDs did
not differ from the controls (data not shown).
Cd was detected in the liver of mice that
received 144 or 14.4 pmol QDs (Figure 6A),
whereas a dose of 1.44 pmol did not result in
detectable amounts of Cd. For amine-QDs,
the amount of Cd in the liver was higher after
24 hr (1.121 ± 0.251 total µg Cd, after injec-
tion of 144 pmol amine-QDs) than after 1 hr
(0.237 ± 0.325 total µg Cd). For carboxyl-
QDs, the amount of Cd in liver did not
change over time (for 144 pmol carboxyl-QDs,
0.898 ± 0.291 total µg Cd after 24 hr vs. 0.904
± 0.260 total µg Cd after 1 hr). In the blood,
we found excess Cd only in mice that received
amine-QDs, and the concentration decreased
over time (Figure 6B). In the lung, we found
no Cd (data not shown).
In vitro platelet aggregation tests. To inves-
tigate whether human and murine platelets can
be activated by QDs, we performed aggregation
studies in PRP. The ADP-induced aggregation
of murine PRP was dose-dependently enhanced
upon preincubation for 1 min with amine-QD
concentrations > 180 pmol/mL (Figure 7A,C).
The effect of carboxyl-QDs on ADP-induced
platelet aggregation was also dose dependent
and even more pronounced. At 180 pmol/mL,
platelet aggregation was elevated, leading to
maximal platelet aggregation starting at
540 pmol/mL carboxyl-QDs (Figure 7B). Even
a low dose of 144 pmol/mL carboxyl-QDs
enhanced ADP-induced platelet aggregation;
the lowest doses (14.4 and 1.44 pmol/mL)
had no effect (Figure 7D). The particles them-
selves (amine-QDs or carboxyl-QDs) did not
cause platelet aggregation in the absence of
ADP. However, carboxyl-QDs induced a
platelet shape change at a concentration of
1,620 pmol/mL (Figure 7E).
Human PRP aggregation was more variably
affected by QDs. Blood from four of six donors
Acute toxicity of quantum dots in mice
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Figure 5. Leukocytes in blood (mean percentage ±
SD) 4 hr after iv administration of carboxyl-QDs or
amine-QDs (1.44, 14.4, or 144 pmol/mouse). Data rep-
resent mean ± SD. Control, n = 8; treatment, n = 6. 
**p < 0.01 for lymphocytes versus control. #p < 0.001 for
neutrophils versus control.
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Figure 6. Tissue Cd distribution in liver (A) and blood
(B) 1, 4, or 24 hr after iv administration of carboxyl-
QDs or amine-QDs (1.44, 14.4, or 144 pmol/mouse).
Control, n = 4; treatment, n = 3. Values below the
detection limit (0.006 mg/L Cd) have been replaced
with one-third of the detection limit.
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Figure 7. In vitro murine platelet aggregation in the absence or presence of ADP. (A and B) Murine PRP with
agonist ADP; the tracings represent preincubation of PRP with different concentrations of amine-QDs (A) or
carboxyl-QDs (B): 0 μg/mL (1), 180 pmol/mL (2), 540 pmol/mL (3), or 1,620 pmol/mL (4). Arrows indicate the time
point of ADP addition. (C and D) Murine PRP with agonist ADP incubated with amine-QDs (C) or carboxyl-
QDs (D) at 0 μg/mL (5), 1.44 pmol/mL (6), 14.4 pmol/mL (7), or 144 pmol/mL (8). (E) Murine PRP without ADP,
incubated with amine-QDs at 540 pmol/mL (9) or 1,080 pmol/mL (10), or with carboxyl-QDs at 540 pmol/mL (11)
or 1,620 pmol/mL (12). The arrowhead indicates the presence of platelet shape change.
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amine-QDs with a mean 2.6-fold increase in
maximal platelet aggregation amplitude, com-
pared with control conditions without QDs;
at 360 pmol/mL, only two of six donors
responded, with a mean 1.7-fold increase. At
lower concentrations, we noted no response. In
the case of carboxyl-QDs, for one donor’s sam-
ple, the platelet aggregation was enhanced 3- or
4-fold at 144 or 14.4 pmol/mL, respectively.
At 360 and 720 pmol/mL, four donors
responded with a mean 2.6- and 3.7-fold
increase, respectively. Figure 8A–D shows the
platelet aggregation proﬁle for one volunteer.
Discussion
Despite industrial and medicinal promise of
nanomaterials, concerns have been expressed
about their possible adverse health effects
(Hoet et al. 2004; Oberdörster et al. 2005b;
Xia et al. 2006). Because nanosized QDs are
monodispersed and fluorescent, they can be
used as good models for testing potential
nanotoxicity. To study the inﬂuence of surface
charge, we used commercially available type I
EviTags, with either carboxyl or amine coat-
ings; QDs of this type with neutral surface
charge are not available. Because this is the
ﬁrst in-depth study speciﬁcally designed to test
the in vivo toxicity of QDs, our purpose was
to assess acute effects and to provide a dose–
response relationship, together with an assess-
ment of the tissue distribution, to identify the
important target organs. Because vascular
thrombi were produced in the lung, we inves-
tigated whether this thrombosis was due to
either platelet activation or activation of coag-
ulation. We examined platelet activation by
assessing the effects of administering QDs on
levels of P-selectin on circulating platelets
(using flow cytometry) and by measuring
platelet aggregation upon in vitro incubation
of murine and human PRP with QDs. The
role of coagulation was assessed by examining
the effects of pretreatment with the anti-
coagulant heparin.
Experts have recommended characterizing
essential physicochemical properties of nano-
particles whenever performing toxicity studies
with nanomaterials (Oberdörster et al. 2005a).
TEM is considered a gold standard for evalu-
ating particle size distribution and shape
(Oberdörster et al. 2005a). However, no satis-
fying TEM images could be obtained for the
QDs used. The coating of the QDs was spread
over the grid, covering the core/shell of the
QDs, which is in line with ﬁndings of others
(Fischer et al. 2006; Gopee et al. 2007; Soo
Choi et al. 2007; Zhu et al. 2007). The sepa-
ration of the coating from the core/shell of the
QDs is thought to be due to the sample
preparation process, including drying of the
samples. As a consequence, no valuable data
about aggregation and size could be obtained
with this method. Nevertheless, sizes can be
measured in solution using DLS. This method
indicated that the amine-QDs were not aggre-
gated, whereas the carboxyl-QDs were poly-
dispersed in water (with the coexistence of two
or three particle sizes) but almost mono-
dispersed in the other tested vehicles. The zeta
potential varied in the different vehicles:
–14.2 mV for amine-QDs and –35.2 mV for
carboxyl-QDs when dispersed in saline.
Because of their unique properties, QDs
are considered ideal probes for in vivo imaging;
low quantities (ranging from 300 pmol/g
down to 0.01 pmol/g) are needed for in vivo
applications (Ballou et al. 2004; Gao et al.
2004; Kim et al. 2004; Larson et al. 2003; So
et al. 2006; Stroh et al. 2005; Tada et al. 2007;
Yu et al. 2007). To establish realistic dose–
response relationships, we tested concentra-
tions from 3,600 pmol down to 1.44 pmol.
Three of four animals that received
3,600 pmol carboxyl-QDs died immediately
upon injection because of massive thrombosis
in the pulmonary vasculature. We also saw
thrombi containing QDs in the lung of ani-
mals receiving 720 or 144 pmol carboxyl-QDs,
and the number of thrombi was proportional
to the dose administered. Carboxyl-QDs
proved more potent in inducing pulmonary
vascular thrombosis than did amine-QDs. A
parallel drop in the circulating platelet count
was induced, which at first suggested the
occurrence of activation of circulating platelets,
with aggregates being retained in the pul-
monary microvasculature. However, although
ADP-induced platelet aggregation was elevated
by QDs in vitro, direct platelet activation by
QDs does not explain the in vivo thrombotic
complications. Indeed, the QDs themselves
did not induce platelet aggregation, although
the carboxyl-QDs induced a platelet shape
change at the highest concentration tested,
indicative of at least some platelet activation.
For both surface properties, we observed a
dose-dependent stimulation of the ADP-trig-
gered platelet aggregation, and it was more
pronounced for the carboxyl-QDs. The signiﬁ-
cance of these in vitro observations is unclear,
because in vivo thrombotic complications
were observed at QD plasma concentrations
below those required for platelet activation
stimulation.
This led us to hypothesize that the throm-
botic events were caused not by platelet activa-
tion but by activation of the coagulation
cascade, especially because massive ﬁbrin ﬁbers
Geys et al.
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Figure 8. Effect of QDs on in vitro ADP-induced platelet aggregation of human PRP. (A and B) Human PRP
from a single donor, incubated with amine-QDs (A) or carboxyl-QDs (B) at concentrations of 0 μg/mL (1),
360 pmol/mL (2), or 720 pmol/mL (3). (C and D) Human PRP from the same volunteer, incubated with amine-
QDs (C) or carboxyl-QDs (D) at concentrations of 0 μg/mL (1), 1.44 pmol/mL (4), 14.4 pmol/mL (5), or
144 μg/mL (6). Arrows indicate the time point of ADP addition.
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were present in the pulmonary thrombi. We
tested this hypothesis by pretreating the mice
with the anticoagulant heparin. With such pre-
treatment, carboxyl-QDs no longer induced
thrombosis in the lung; in addition, circulating
platelet numbers were no longer decreased.
Moreover, the platelet P-selectin levels indi-
cated no evidence of in vivo platelet activation
in the presence of heparin. These findings
allow us to conclude that the negatively
charged surface of carboxyl-QDs triggers coag-
ulation, probably via contact activation, thus
leading to ﬁbrin formation and simultaneous
platelet activation by thrombin, which is a
potent agonist of platelet activation via PAR1
protease-activated receptors on platelets
(Kataoka et al. 2003), which function is ful-
filled by PAR4 receptors on mouse platelets.
This explains the more pronounced effect of
carboxyl-QDs compared with amine-QDs. In
previous studies (Nemmar et al. 2002), we
found that positively charged amine polystyrene
nanoparticles enhanced the ADP-triggered
platelet aggregation more strongly than did
negatively charged carboxyl polystyrene nano-
particles. In contrast to the QDs used here,
these polystyrene particles had no effect on
coagulation tests (Nemmar et al. 2002). Those
findings do not contradict our present data,
where coagulation induction, rather than
platelet activation, is triggered by the negatively
charged QDs. Polystyrene beads have a differ-
ent surface chemistry than do the presently
studied QDs. In addition, the reported zeta
potentials for the amine and carboxyl poly-
styrene beads were –44 mV and –41 mV
(Nemmar et al. 2002), respectively, and hence
not comparable with our QDs, with zeta
potentials of –14.2 mV and –35.2 mV for
amine-QDs and carboxyl-QDs, respectively.
The ﬂuorescence microscopy observations
are in agreement with the measurements of Cd
in the organs. The relatively high Cd concen-
tration in the QDs allowed concentrations
down to 2.52 pmol to be detected by ICP-OES
(assessed by a QD standard curve), resulting in
a more powerful detection technique com-
pared with ﬂuorescence microscopy. In tissue
distribution studies, QDs were found mainly in
the lung, liver, and blood, with a difference
between amine-QDs and carboxyl-QDs.
Carboxyl-QDs were cleared from the blood
1 hr after iv injection. The absence of Cd in the
kidney indicates that the QDs were not dis-
solved in the body during this time frame.
Other biodistribution studies of QDs indicated
liver, lung, kidney, and spleen as main sites of
deposition (Fischer et al. 2006; Gopee et al.
2007; Soo Choi et al. 2007; Yang et al. 2007);
the hydrodynamic diameter and the surface of
the QDs are critical factors in blood half-life,
tissue distribution pattern, and excretion
(Fischer et al. 2006; Soo Choi et al. 2007).
Surface coating, doses, and time windows
examined in these studies differ significantly
from our study.
The concentrations used in our toxicity
study agree with the quantities needed for
in vivo applications (Ballou et al. 2004; Gao
et al. 2004; Kim et al. 2004; Larson et al.
2003; So et al. 2006; Stroh et al. 2005; Tada
et al. 2007; Yu et al. 2007); however, linking
our results to other studies is a challenge
because the metrics deﬁning dosage concentra-
tions vary in the reported literature.
In conclusion, we conducted an acute
in vivo toxicity study with commercially avail-
able carboxyl-QDs and amine-QDs using a
large range of doses that encompass doses used
for in vivo applications (3,600 pmol down to
1.44 pmol). We characterized the particles
before administration and evaluated toxicity
end points at different time points. At high
doses, the QDs caused pulmonary vascular
thrombosis, with carboxyl-QDs being more
potent in inducing this effect than amine-
QDs. Because ﬁbrin ﬁbers were present in the
thrombi and because pretreatment with
heparin abolished the thrombotic effects, we
speculate that negatively charged QDs activate
the coagulation cascade via contact activation.
We saw an effect of surface charge in all the
parameters tested. Lower doses of 14.4 pmol
or 1.44 pmol did not elicit acute adverse
effects. This is the ﬁrst comprehensive evalua-
tion of the hazard of injected QDs and
emphasizes that surface charge is an important
parameter in assessing nanotoxicity.
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